Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

抗体依赖性细胞介导的细胞毒性 抗原 抗体 细胞毒性 癌症研究 单克隆抗体 免疫学 生物 分子生物学 体外 生物化学
作者
Thorsten Ross,Uwe Reusch,Susanne Wingert,Torsten Haneke,Katja Klausz,Anna-Kathrin Otte,Natalie Schub,Stefan Knackmuss,Thomas Müller,Kristina Ellwanger,Ivica Fucek,Ute Schniegler‐Mattox,Joachim Koch,Thomas Valerius,Martin Gramatzki,Matthias Peipp,Michael Tesar,Erich Rajkovic,Martin Treder
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 1927-1927 被引量:28
标识
DOI:10.1182/blood-2018-99-118970
摘要

Abstract Natural killer (NK) cells are crucial effector cells of the innate immune system capable of rapidly recognizing and eliminating infected, stressed and malignant cells. NK cells are also the prime mediators of antibody-dependent cell-mediated cytotoxicity (ADCC), a potent mechanism of anti-viral immunity that has been applied to cancer therapy by targeting tumor-expressed surface antigens using monoclonal antibodies (mAbs). Classical ADCC is mediated by low affinity Fc-mediated engagement of NK cells via FcγRIIIA (CD16A) and is modulated by differences in target antigen expression levels. While high potency of therapeutic mAbs is achieved when target antigen is available at high density, potency and efficacy decrease substantially when copy numbers are low. Classical ADCC also needs to overcome the inhibitory effect of competing serum IgG and is negatively affected by a low affinity polymorphism of CD16A (158F) that is prevalent in approximately 8 of 10 individuals. Hence, classical Fc-mediated ADCC does not fully utilize the therapeutic potential of NK cell cytotoxicity. B cell maturation antigen (BCMA) has emerged as a promising target for treatment of multiple myeloma (MM) due to its near universal expression on tumor cells and restricted expression in non-malignant tissues. Numerous therapeutic approaches are currently investigated clinically and pre-clinically and target BCMA, however, none of these are aimed at fully utilizing NK cell-mediated ADCC. Low copy numbers of BCMA (approx. 40-15,000) might limit the activity of classical mAbs against BCMA, especially in the presence of high serum concentrations of paraprotein. In addition, NK cells may be ideally suited to target minimal residual disease immediately before or after autologous stem cell transplantation. Consequently, by efficiently redirecting NK cell cytotoxicity to BCMA+ myeloma, AFM26 used alone or in combination with other approaches may provide a novel, optimized treatment strategy. Here we describe development of AFM26, a BCMA and CD16A-directed tetravalent bispecific antibody that selectively engages CD16A+ effector cells, including NK cells, and is designed to overcome the limitations of classical ADCC. AFM26 is based on the recently launched Redirected, Optimized Cell Killing (ROCK) antibody platform and combines high affinity CD16A-directed effector cell engagement with IgG-like pharmacokinetics and manufacturability. We demonstrate that AFM26 interacts with NK cells with high avidity independently of CD16A polymorphism and in presence of competing IgG. NK cell-mediated lysis of BCMA+ target cell lines induced by AFM26 is largely independent of BCMA expression levels with high potency and efficacy observed at low copy numbers (<200), as confirmed by autologous lysis of primary MM cells in vitro. Despite more potent and efficacious in vitro lysis, release of inflammatory cytokines is comparable with classical antibody formats. We further demonstrate anti-tumor activity of AFM26 in combination with adoptive transfer of primary human NK cells in vivo using human IL-15-transgenic NOG mice. AFM26 therefore is a promising agent currently in preclinical development to fully unlock NK cell cytotoxicity for BCMA-directed immunotherapy of MM. Disclosures Ross: Affimed: Employment. Reusch:Affimed: Employment. Wingert:Affimed: Employment. Haneke:Affimed: Employment. Klausz:Affimed: Research Funding. Otte:Affimed: Research Funding. Schub:Affimed: Research Funding. Knackmuss:Affimed: Employment. Müller:Affimed: Employment. Ellwanger:Affimed: Employment. Fucek:Affimed: Employment. Schniegler-Mattox:Affimed: Employment. Koch:Affimed GmbH: Employment. Valerius:Affimed: Research Funding. Gramatzki:Affimed: Research Funding. Peipp:Affimed: Research Funding. Tesar:Affimed: Employment. Rajkovic:Affimed: Employment. Treder:Affimed GmbH: Employment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lixun完成签到 ,获得积分10
刚刚
刚刚
1秒前
1秒前
逆光发布了新的文献求助10
1秒前
酷炫的康完成签到,获得积分10
1秒前
1秒前
Tardes发布了新的文献求助10
1秒前
红梅发布了新的文献求助10
1秒前
狂野妙菱完成签到,获得积分10
2秒前
星辰大海的应助被吴阳采纳,获得10
2秒前
2秒前
超级送终发布了新的文献求助10
2秒前
狂野的勒完成签到,获得积分10
2秒前
包容的初之完成签到,获得积分10
3秒前
NexusExplorer的应助被orange采纳,获得10
3秒前
无极微光的应助被cora采纳,获得20
3秒前
脑洞疼的应助被suer采纳,获得10
4秒前
田様的应助被小米步枪的科研采纳,获得10
4秒前
呆呆茹完成签到,获得积分10
4秒前
完美犀牛发布了新的文献求助10
4秒前
5秒前
狂野的勒发布了新的文献求助20
5秒前
于洛铱完成签到,获得积分10
5秒前
诚心的凡雁的应助被刘欣睿采纳,获得10
5秒前
浴享发布了新的文献求助10
6秒前
6秒前
万能图书馆的应助被sunzp采纳,获得10
6秒前
打打的应助被幻天游采纳,获得10
6秒前
7秒前
箫笙发布了新的文献求助10
7秒前
7秒前
科研通AI65的应助被聂的苏采纳,获得50
7秒前
7秒前
7秒前
8秒前
pppyrus完成签到,获得积分10
8秒前
斯文败类的应助被焦焦采纳,获得10
8秒前
调皮的香寒完成签到 ,获得积分10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175853
求助须知:如何正确求助?哪些是违规求助? 9567457
关于积分的说明 21792632
捐赠科研通 7770447
什么是DOI,文献DOI怎么找? 3431918
关于科研通互助平台的介绍 2556276
邀请新用户注册赠送积分活动 2477418